))
Using Drug Implants to Reduce Burden of Medication Adherence with Dr. Adam Mendelsohn Vivani Medical
Manage episode 354828035 series 2949197
Content provided by Karen Jagoda. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karen Jagoda or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Dr. Adam Mendelsohn, the CEO of Vivani Medical, seeks to enable people to receive the maximum potential benefits from medicines while minimizing the associated burden with taking those medicines. Drug implants overcome forgetfulness, procrastination, and other human behavior that impacts medication adherence. They anticipate expanding partnerships with various drug molecules and indications around their nano portal drug delivery technology.
Adam elaborates, "When these medicines are evaluated in randomized clinical trial settings, they produce fantastic results. But these results don't translate into the real world in the way that they possibly could, and the primary reason for this is, as Charles Everett Koop, former US Surgeon General, once said, "Drugs don't work in people that don't take them." So, we are aiming to address this by developing miniature subdermal implants that can provide steady therapeutic doses over many months, guaranteeing medication adherence for these patients and, hopefully, improving real-world outcomes for chronic diseases."
"The underlying technology we've demonstrated works with peptide therapeutics and some of the larger protein-based therapeutics. These are larger hydrophilic molecules that some of the other implant technologies have not been shown to be compatible with. We do believe that the technology could work with smaller hydrophobic molecules as well."
"Down the road, we anticipate developing a portfolio of drug implants that can address adherence across a wide range of chronic diseases. But we have been pretty focused on a few different peptides and one in particular that we are preparing to begin a phase II clinical study early next year with around the type 2 diabetes indication. But the underlying technology is a platform that we think does have broad applicability."
#VivaniMedical #MedicationAdherence #DrugImplants #ChronicDiseases #Type2Diabetes
1725 episoade
Distribuie
